HALO logo
halo search icon
Rein Therapeutics, Inc
Rein Therapeutics, Inc
RNTX · NAS

Rein Therapeutics, Inc

US$0.97

Price Arrow-0.0254 (-2.553%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig CandleHALO AllHALO Consensus Value
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Rein Therapeutics, Inc Overview

RNTX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About RNTX

icon

Telephone

1.737.802.1989

icon

Address

Suite 250, 12407 North Mopac Expressway, Austin, TX 78758

Description

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

RNTX Price Chart

Key Stats

Market Cap

US$85.11M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.98 - 2.21

Trade Value (12mth)

US$156,090.00

1 week

-5.24%

1 month

-46.79%

YTD

-20.4%

1 year

-48.71%

All time high

309.60

Key Fundamentals

EPS 3 yr Growth

-67.40%

EBITDA Margin

0.00%

Operating Cashflow

-$19m

Free Cash Flow Return

-54.30%

ROIC

-139.90%

Interest Coverage

0.00

Quick Ratio

0.70

Other Data

Shares Outstanding (Fully Diluted)

30m

HALO Sector

Healthcare

Next Company Report Date

03-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

RNTX Announcements

Latest Announcements

DateAnnouncements
15 May 26
15 May 26
15 May 26
05 May 26
05 May 26

RNTX Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-3.42-3.51-1.96locklocklock
EPS (Fully Diluted)
$locklocklocklock-3.42-3.51-1.96locklocklock
Growth
%locklocklocklock43.2-2.544.1locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Rein Therapeutics, Inc (RNTX:NAS)?
Halo FAQ
The current share price of Rein Therapeutics, Inc (RNTX:NAS) is USD$0.97.
What is the 52-week high share price for Rein Therapeutics, Inc (RNTX:NAS)?
Halo FAQ
The 52-week high share price for Rein Therapeutics, Inc (RNTX:NAS) is USD$2.21.
What is the 52-week low share price for Rein Therapeutics, Inc (RNTX:NAS)?
Halo FAQ
The 52-week low share price for Rein Therapeutics, Inc (RNTX:NAS) is USD$0.98.
What is the dividend yield for Rein Therapeutics, Inc (RNTX:NAS)?
Halo FAQ
Rein Therapeutics, Inc (RNTX:NAS) does not pay a dividend.
What was Rein Therapeutics, Inc (RNTX:NAS) last dividend payment?
Halo FAQ
Rein Therapeutics, Inc (RNTX:NAS) does not pay a dividend.
What is the franking level for Rein Therapeutics, Inc (RNTX:NAS)?
Halo FAQ
Rein Therapeutics, Inc (RNTX:NAS) has a franking level of 0.00%.
In which sector is Rein Therapeutics, Inc (RNTX:NAS) classified?
Halo FAQ
Rein Therapeutics, Inc (RNTX:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.